171 related articles for article (PubMed ID: 15932369)
1. Epithelial cell proliferation of the colonic mucosa in diverticular disease: a case-control study.
Morini S; Hassan C; Zullo A; De Francesco V; Burattini O; Margiotta M; Panella C; Ierardi E
Aliment Pharmacol Ther; 2005 Jun; 21(11):1385-90. PubMed ID: 15932369
[TBL] [Abstract][Full Text] [Related]
2. Effect of mesalazine on epithelial cell proliferation in colonic diverticular disease.
Tursi A; Brandimarte G; Elisei W; Giorgetti GM; Inchingolo CD; Aiello F
Dig Liver Dis; 2008 Sep; 40(9):737-42. PubMed ID: 18387861
[TBL] [Abstract][Full Text] [Related]
3. Epithelial cell proliferation of the colonic mucosa in different degrees of colonic diverticular disease.
Tursi A; Brandimarte G; Elisei W; Inchingolo CD; Aiello F
J Clin Gastroenterol; 2006 Apr; 40(4):306-11. PubMed ID: 16633102
[TBL] [Abstract][Full Text] [Related]
4. Meta-analysis: long-term therapy with rifaximin in the management of uncomplicated diverticular disease.
Bianchi M; Festa V; Moretti A; Ciaco A; Mangone M; Tornatore V; Dezi A; Luchetti R; De Pascalis B; Papi C; Koch M
Aliment Pharmacol Ther; 2011 Apr; 33(8):902-10. PubMed ID: 21366632
[TBL] [Abstract][Full Text] [Related]
5. Rifaximin improves symptoms of acquired uncomplicated diverticular disease of the colon.
Latella G; Pimpo MT; Sottili S; Zippi M; Viscido A; Chiaramonte M; Frieri G
Int J Colorectal Dis; 2003 Jan; 18(1):55-62. PubMed ID: 12458383
[TBL] [Abstract][Full Text] [Related]
6. [Role of rifaximin in the treatment of colonic diverticular disease].
Moretti A; Spagnolo A; Mangone M; Chiesara F; Aratari A; Papi C; Koch M
Clin Ter; 2012; 163(1):33-8. PubMed ID: 22362232
[TBL] [Abstract][Full Text] [Related]
7. Involvement of central immunity in uncomplicated diverticular disease.
Cianci R; Iacopini F; Petruzziello L; Cammarota G; Pandolfi F; Costamagna G
Scand J Gastroenterol; 2009; 44(1):108-15. PubMed ID: 18759154
[TBL] [Abstract][Full Text] [Related]
8. Mesalazine and rifaximin in symptomatic uncomplicated diverticular disease.
Festi D; Colecchia A
Am J Gastroenterol; 2009 Feb; 104(2):532. PubMed ID: 19174809
[No Abstract] [Full Text] [Related]
9. Management of diverticular disease: is there room for rifaximin?
Papi C; Koch M; Capurso L
Chemotherapy; 2005; 51 Suppl 1():110-4. PubMed ID: 15855755
[TBL] [Abstract][Full Text] [Related]
10. Transient lactose malabsorption in patients affected by symptomatic uncomplicated diverticular disease of the colon.
Tursi A; Brandimarte G; Giorgetti GM; Elisei W
Dig Dis Sci; 2006 Mar; 51(3):461-5. PubMed ID: 16614952
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of rifaximin on symptoms of uncomplicated diverticular disease of the colon. A pilot multicentre open trial. Diverticular Disease Study Group.
Papi C; Ciaco A; Koch M; Capurso L
Ital J Gastroenterol; 1992 Oct; 24(8):452-6. PubMed ID: 1330083
[TBL] [Abstract][Full Text] [Related]
12. Does rifaximin prevent complications of diverticular disease? A retrospective study.
Pistoia MA; Lombardi L; Rossi M; Vittorini C; Cavaliere GF; Pistoia F
Eur Rev Med Pharmacol Sci; 2004; 8(6):283-7. PubMed ID: 15745388
[TBL] [Abstract][Full Text] [Related]
13. Uncomplicated diverticular disease: innate and adaptive immunity in human gut mucosa before and after rifaximin.
Cianci R; Frosali S; Pagliari D; Cesaro P; Petruzziello L; Casciano F; Landolfi R; Costamagna G; Pandolfi F
J Immunol Res; 2014; 2014():696812. PubMed ID: 25133198
[TBL] [Abstract][Full Text] [Related]
14. Rifaximin in the management of colonic diverticular disease.
Latella G; Scarpignato C
Expert Rev Gastroenterol Hepatol; 2009 Dec; 3(6):585-98. PubMed ID: 19929580
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of mesalazine in the treatment of symptomatic diverticular disease.
Di Mario F; Aragona G; Leandro G; Comparato G; Fanigliulo L; Cavallaro LG; Cavestro GM; Iori V; Maino M; Moussa AM; Gnocchi A; Mazzocchi G; Franzé A
Dig Dis Sci; 2005 Mar; 50(3):581-6. PubMed ID: 15810646
[TBL] [Abstract][Full Text] [Related]
16. Review article: the current and evolving treatment of colonic diverticular disease.
Tursi A; Papagrigoriadis S
Aliment Pharmacol Ther; 2009 Sep; 30(6):532-46. PubMed ID: 19549266
[TBL] [Abstract][Full Text] [Related]
17. Increased presence of serotonin-producing cells in colons with diverticular disease may indicate involvement in the pathophysiology of the condition.
Banerjee S; Akbar N; Moorhead J; Rennie JA; Leather AJ; Cooper D; Papagrigoriadis S
Int J Colorectal Dis; 2007 Jun; 22(6):643-9. PubMed ID: 17086395
[TBL] [Abstract][Full Text] [Related]
18. Rifaximin plus mesalazine followed by mesalazine alone is highly effective in obtaining remission of symptomatic uncomplicated diverticular disease.
Brandimarte G; Tursi A
Med Sci Monit; 2004 May; 10(5):PI70-3. PubMed ID: 15114281
[TBL] [Abstract][Full Text] [Related]
19. Long-term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis.
Vlachogiannakos J; Viazis N; Vasianopoulou P; Vafiadis I; Karamanolis DG; Ladas SD
J Gastroenterol Hepatol; 2013 Mar; 28(3):450-5. PubMed ID: 23216382
[TBL] [Abstract][Full Text] [Related]
20. Proliferative patterns of rectal mucosa as predictors of advanced colonic neoplasms in routinely processed rectal biopsies.
Paspatis GA; Zizi A; Chlouverakis GJ; Giannikaki ES; Vasilakaki T; Elemenoglou I; Karamanolis DG
Am J Gastroenterol; 1998 Sep; 93(9):1472-7. PubMed ID: 9732928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
